医学
结直肠癌
间质细胞
新辅助治疗
CD8型
T细胞
渗透(HVAC)
化疗
放化疗
病态的
肿瘤科
免疫组织化学
癌症研究
癌症
内科学
病理
免疫系统
免疫学
乳腺癌
物理
热力学
作者
Ken Imaizumi,Toshihiro Suzuki,Motohiro Kojima,Manami Shimomura,Naoki Sakuyama,Yuichiro Tsukada,Takeshi Sasaki,Yuji Nishizawa,Akinobu Taketomi,Masaaki Ito,Tetsuya Nakatsura
摘要
Abstract Chemoradiotherapy (CRT) is the standard neoadjuvant therapy for locally advanced rectal cancer (RC). However, neoadjuvant chemotherapy (NAC) also shows favorable outcomes. Although the immunological environment of RC has been thoroughly discussed, the effect of NAC on it is less clear. Here, we investigated the immunological microenvironment, including T cell infiltration, activation, and topological distribution, of resected RC tissue after neoadjuvant therapies and evaluated the correlation between T cell subsets and patient prognosis. Rectal cancer patients (n = 188) were enrolled and categorized into 3 groups, namely CRT (n = 41), NAC (n = 46), and control (surgery alone; n = 101) groups. Characterization of residual carcinoma cells and T cell subsets in resected tissues was performed using multiplex fluorescence immunohistochemistry. The densities of total and activated (Ki67 high ) T cells in tissues after NAC, but not CRT, were higher than in control. In both CRT and NAC groups, patients presenting with higher treatment effects showed aggressive infiltration of T cell subsets into carcinomas. Multivariate analyses of pathological and immunological features and prognosis revealed that carcinoma Ki67 high CD4 + T cells after CRT and stromal Ki67 high CD8 + T cells after NAC are important prognostic factors, respectively. Our results suggest that evaluation of T cell activation with Ki67 expression and its tumor localization can be used to determine the prognosis of advanced RC after neoadjuvant therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI